| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A cascade linking A-beta through Tau missorting to destruction of dendritic microtubules by spastin
|
Zempel, H.
|
|
2014
|
35 |
S1 |
p. S14-
1 p.
|
artikel
|
| 2 |
A clinical trial investigating the effects of souvenaid in prodromal Alzheimer's disease: progress and baseline characteristics of the lipididiet study
|
Soininen, Hilkka
|
|
2014
|
35 |
S1 |
p. S20-
1 p.
|
artikel
|
| 3 |
Acute care units for Alzheimer patients
|
Zekry, Dina
|
|
2014
|
35 |
S1 |
p. S26-S27
2 p.
|
artikel
|
| 4 |
Advances in active and passive immunotherapy for Alzheimer's disease
|
Hock, Christoph
|
|
2014
|
35 |
S1 |
p. S10-
1 p.
|
artikel
|
| 5 |
Aging without dementia: only a dream?
|
Fratiglioni, Laura
|
|
2014
|
35 |
S1 |
p. S7-
1 p.
|
artikel
|
| 6 |
Agitation and Aggression in Alzheimer's Disease (AD): Study Design and Outcome Measures in a Trial of Scyllo-inositol (ELND005 HARMONY AD Study)
|
Abushakra, Susan
|
|
2014
|
35 |
S1 |
p. S1-
1 p.
|
artikel
|
| 7 |
Albumin as a potential therapeutic agent in Alzheimer's disease
|
Jalan, Rajiv
|
|
2014
|
35 |
S1 |
p. S11-
1 p.
|
artikel
|
| 8 |
Alzheimer's Management by Albumin Replacement (AMBAR)
|
Lopez, Oscar
|
|
2014
|
35 |
S1 |
p. S14-
1 p.
|
artikel
|
| 9 |
Alzheimer Therapy: why should we move from a-beta to TAU?
|
Giacobini, Ezio
|
|
2014
|
35 |
S1 |
p. S8-S9
2 p.
|
artikel
|
| 10 |
A new APP mutation prevents synaptic degeneration in Alzheimer Disease model
|
Borsello, Tiziana
|
|
2014
|
35 |
S1 |
p. S3-S4
2 p.
|
artikel
|
| 11 |
A novel multipotent sigma 1/M1 muscarinic activator for a comprehensive therapeutic strategy in Alzheimer's disease
|
Fisher, Abraham
|
|
2014
|
35 |
S1 |
p. S6-S7
2 p.
|
artikel
|
| 12 |
A novel, natural derivative with promising efficacy on brain ischemic injury
|
Ruan, Zhi
|
|
2014
|
35 |
S1 |
p. S27-
1 p.
|
artikel
|
| 13 |
A Novel Therapeutic Target Against Alzeimer's Disease: HRD1 as Endoplasmic Reticulum Stress-Related Ubiquitin Ligase
|
Nomura, Yasuyuki
|
|
2014
|
35 |
S1 |
p. S17-
1 p.
|
artikel
|
| 14 |
Anti-inflammatory treatments and Alzheimer's disease: a ‘double-edged sword’?
|
Breitner, John
|
|
2014
|
35 |
S1 |
p. S4-
1 p.
|
artikel
|
| 15 |
Approach to care of Alzheimer's patients in Switzerland: the example of the Canton de Vaud
|
Büla, Christophe J.
|
|
2014
|
35 |
S1 |
p. S4-S5
2 p.
|
artikel
|
| 16 |
A regulatory perspective on Alzheimer's disease drug development
|
Mantua, Valentina
|
|
2014
|
35 |
S1 |
p. S14-S15
2 p.
|
artikel
|
| 17 |
Are older brains getting younger? Changes in cerebral amyloid deposition over a 30-year period
|
Kövári, Enikö
|
|
2014
|
35 |
S1 |
p. S13-
1 p.
|
artikel
|
| 18 |
Astroglia and microglia imaging markers in the progression of Alzheimer's disease
|
Nordberg, Agneta
|
|
2014
|
35 |
S1 |
p. S17-S18
2 p.
|
artikel
|
| 19 |
Asymptomatic individuals at risk for alzheimer's disease: who are they and what can we do with them?
|
Dubois, Bruno
|
|
2014
|
35 |
S1 |
p. S6-
1 p.
|
artikel
|
| 20 |
A Synaptotoxic Pathway from Aβ oligomer to Prion Protein to mGluR5 to F kinase in Alzheimer's Disease
|
Strittmatter, Stephen
|
|
2014
|
35 |
S1 |
p. S21-
1 p.
|
artikel
|
| 21 |
Author Index
|
|
|
2014
|
35 |
S1 |
p. S2-S3
2 p.
|
artikel
|
| 22 |
AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF Aβ peptides following single- and multiple-dose administration
|
Alexander, Robert
|
|
2014
|
35 |
S1 |
p. S2-
1 p.
|
artikel
|
| 23 |
BACE1 inhibition as a therapeutic strategy for Alzheimer's disease
|
Vassar, Robert
|
|
2014
|
35 |
S1 |
p. S23-
1 p.
|
artikel
|
| 24 |
Biomarkers and the neuropsychology of the ageing-brain cognitive diseases
|
Démonet, Jean-François
|
|
2014
|
35 |
S1 |
p. S5-
1 p.
|
artikel
|
| 25 |
Brain atrophy in MCI and presymptomatic neurodegeneration: insights from, and advantages of, longitudinal studies
|
Weston, P.S.J.
|
|
2014
|
35 |
S1 |
p. S7-
1 p.
|
artikel
|
| 26 |
BRAINCHECK: A new screening tool for cognitive impairment in the elderly – combining patient assessment with caregiver information
|
Monsch, Andreas U.
|
|
2014
|
35 |
S1 |
p. S16-
1 p.
|
artikel
|
| 27 |
Challenges in the pharmacotherapy of apathy in Alzheimer's disease
|
Lanctôt, Krista
|
|
2014
|
35 |
S1 |
p. S13-
1 p.
|
artikel
|
| 28 |
Cholinesterase Inhibitors and Alzheimer Therapy: Thirty Years of Experience
|
Farlow, Martin
|
|
2014
|
35 |
S1 |
p. S6-
1 p.
|
artikel
|
| 29 |
Clinical value of amyloid imaging. The Dutch experience
|
Scheltens, Philip
|
|
2014
|
35 |
S1 |
p. S19-
1 p.
|
artikel
|
| 30 |
Cognitive and behavioural reserve in Alzheimer's Disease: PET studies
|
Garibotto, Valentina
|
|
2014
|
35 |
S1 |
p. S8-
1 p.
|
artikel
|
| 31 |
Communicating the diagnosis of Alzheimer's disease: Dilemmas and perspectives
|
Gauthier, Serge
|
|
2014
|
35 |
S1 |
p. S8-
1 p.
|
artikel
|
| 32 |
Contents
|
|
|
2014
|
35 |
S1 |
p. OBC-
1 p.
|
artikel
|
| 33 |
Contents
|
|
|
2014
|
35 |
S1 |
p. v-x
nvt p.
|
artikel
|
| 34 |
CSF biomarkers for AD: state of the art and new developments
|
Blennow, Kaj
|
|
2014
|
35 |
S1 |
p. S3-
1 p.
|
artikel
|
| 35 |
D2 agonist administration restores altered cortical plasticity in Alzheimer's disease patients
|
Di Lorenzo, Francesco
|
|
2014
|
35 |
S1 |
p. S5-S6
2 p.
|
artikel
|
| 36 |
Decoding Alzheimer's in the Age of Genome-Wide Analyses
|
Tanzi, Rudolph E.
|
|
2014
|
35 |
S1 |
p. S22-
1 p.
|
artikel
|
| 37 |
Dementia in the developing world: risk, impact, and prevention
|
Albanese, Emiliano
|
|
2014
|
35 |
S1 |
p. S1-S2
2 p.
|
artikel
|
| 38 |
Dementia 3-month after stroke is due to medial temporal atrophy
|
Caratozzolo, S.
|
|
2014
|
35 |
S1 |
p. S18-
1 p.
|
artikel
|
| 39 |
Deregulated microRNA-132-3p in Alzheimer's disease
|
Soreq, Hermona
|
|
2014
|
35 |
S1 |
p. S21-
1 p.
|
artikel
|
| 40 |
Designed multi functional drugs targeting neuroprotection, neurorestoration and mitochondrial biogenesis via activation of HIF1α, SIRT1, PGC-1α and Tfam
|
Youdim, Moussa B.H.
|
|
2014
|
35 |
S1 |
p. S26-
1 p.
|
artikel
|
| 41 |
Developing and implementing provincial Alzheimer Strategies Lessons learned from the Quebec Alzheimer Plan
|
Bergman, Howard
|
|
2014
|
35 |
S1 |
p. S3-
1 p.
|
artikel
|
| 42 |
Diagnosis and assessment of apathy
|
Robert, Philippe
|
|
2014
|
35 |
S1 |
p. S18-S19
2 p.
|
artikel
|
| 43 |
Diagnostic value of [18F]flutemetamol amyloid PET: comparison between imaging and neuropathology
|
Thal, Dietmar R.
|
|
2014
|
35 |
S1 |
p. S22-
1 p.
|
artikel
|
| 44 |
Dominantly inherited Alzheimer's disease, an opportunity for early intervention
|
Morris, John C.
|
|
2014
|
35 |
S1 |
p. S16-
1 p.
|
artikel
|
| 45 |
Down – regulation of APP processing reduce TAU and Aβ pathology
|
Solomon, Beka
|
|
2014
|
35 |
S1 |
p. S20-S21
2 p.
|
artikel
|
| 46 |
Early and late inflammation in Alzheimer's pathology
|
Cuello, A. Claudio
|
|
2014
|
35 |
S1 |
p. S5-
1 p.
|
artikel
|
| 47 |
Editorial Advisory Board
|
|
|
2014
|
35 |
S1 |
p. IFC-
1 p.
|
artikel
|
| 48 |
Effect of Physical Exercise on Alzheimer's Disease
|
Waldemar, Gunhild
|
|
2014
|
35 |
S1 |
p. S24-S25
2 p.
|
artikel
|
| 49 |
Evaluation of driving in dementia: an issue of mobility and safety
|
Huber, Philippe
|
|
2014
|
35 |
S1 |
p. S10-S11
2 p.
|
artikel
|
| 50 |
Factors that affect lifespan in mild versus moderate Alzheimer's disease
|
Wattmo, Carina
|
|
2014
|
35 |
S1 |
p. S25-
1 p.
|
artikel
|
| 51 |
18F-GE180 PET imaging of neuroinflammation in aging and Alzheimer's disease in mice.
|
Lemere, Cynthia A.
|
|
2014
|
35 |
S1 |
p. S14-
1 p.
|
artikel
|
| 52 |
First-in-man and First-in-class Tau Vaccine
|
Novak, Michal
|
|
2014
|
35 |
S1 |
p. S18-
1 p.
|
artikel
|
| 53 |
Focusing on ApoE: a viable strategy for Alzheimer therapy
|
Michaelson, Daniel M.
|
|
2014
|
35 |
S1 |
p. S15-S16
2 p.
|
artikel
|
| 54 |
Gait analysis as an early marker for Alzheimer's disease
|
Kressig, Reto W.
|
|
2014
|
35 |
S1 |
p. S13-
1 p.
|
artikel
|
| 55 |
How aggressive should prevention treatments be against Alzheimer's disease?
|
Gauthier, Serge
|
|
2014
|
35 |
S1 |
p. S8-
1 p.
|
artikel
|
| 56 |
Integrating imaging and non imaging markers into a clinical context
|
Frisoni, Giovanni B.
|
|
2014
|
35 |
S1 |
p. S7-S8
2 p.
|
artikel
|
| 57 |
Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques
|
Glabe, Charles
|
|
2014
|
35 |
S1 |
p. S9-
1 p.
|
artikel
|
| 58 |
Is ADAM-10 a valid target for Alzheimer therapy?
|
DiLuca, Monica
|
|
2014
|
35 |
S1 |
p. S6-
1 p.
|
artikel
|
| 59 |
Is essential tremor a dementing neurodegenerative disease?
|
Elble, Rodger J.
|
|
2014
|
35 |
S1 |
p. S6-
1 p.
|
artikel
|
| 60 |
Is Neurodegeneration Caused by A-beta?
|
Jagust, William
|
|
2014
|
35 |
S1 |
p. S11-
1 p.
|
artikel
|
| 61 |
Longitudinal Cognitive Performance in the Oldest Old with no Dementia: A-Beta or Other Pathologies?
|
Kawas, Claudia H.
|
|
2014
|
35 |
S1 |
p. S12-
1 p.
|
artikel
|
| 62 |
Mid-range molecular weight oligomers in the normal and Alzheimer brain: Clinico-pathological correlations
|
Giannakopoulos, Panteleimon
|
|
2014
|
35 |
S1 |
p. S9-
1 p.
|
artikel
|
| 63 |
MRI Markers of microvascular pathology and hemorrhagic risk
|
Werring, David J.
|
|
2014
|
35 |
S1 |
p. S25-
1 p.
|
artikel
|
| 64 |
Multi-domain intervention studies to prevent dementia and AD
|
Kivipelto, Miia
|
|
2014
|
35 |
S1 |
p. S12-
1 p.
|
artikel
|
| 65 |
Multi-tracer imaging concept in Alzheimer's disease
|
Kantarci, Kejal
|
|
2014
|
35 |
S1 |
p. S11-S12
2 p.
|
artikel
|
| 66 |
NAP (davunetide) mechanism of microtubule/autophagy protection: discovery of new therapeutic targets and pipeline products
|
Gozes, Illana
|
|
2014
|
35 |
S1 |
p. S10-
1 p.
|
artikel
|
| 67 |
Neurobiology of apathy in Alzheimer's disease - brain imaging insights and implications
|
Sultzer, David
|
|
2014
|
35 |
S1 |
p. S21-S22
2 p.
|
artikel
|
| 68 |
NeuroImaging in Autosomal Dominant Alzheimer's Disease
|
Fleisher, Adam S.
|
|
2014
|
35 |
S1 |
p. S7-
1 p.
|
artikel
|
| 69 |
New criteria for vascular cognitive impairment
|
Skoog, Ingmar
|
|
2014
|
35 |
S1 |
p. S20-
1 p.
|
artikel
|
| 70 |
New developments in molecular imaging of the pathology of neurodegeneration
|
Villemagne, Victor L.
|
|
2014
|
35 |
S1 |
p. S24-
1 p.
|
artikel
|
| 71 |
New technologies and dementia
|
Tsolaki, Magda
|
|
2014
|
35 |
S1 |
p. S22-S23
2 p.
|
artikel
|
| 72 |
Next frontiers in Alzheimer's disease therapy
|
Fontoura, Paulo
|
|
2014
|
35 |
S1 |
p. S7-
1 p.
|
artikel
|
| 73 |
Nicotinic agonists for Alzheimer therapy
|
Koenig, Gerhard
|
|
2014
|
35 |
S1 |
p. S12-
1 p.
|
artikel
|
| 74 |
Non-pharmacological intervention for memory decline
|
Zanetti, Orazio
|
|
2014
|
35 |
S1 |
p. S26-
1 p.
|
artikel
|
| 75 |
Novel Targets, Innovative Methodology, and Implications for Clinical Development
|
Murphy, Michal F.
|
|
2014
|
35 |
S1 |
p. S17-
1 p.
|
artikel
|
| 76 |
Oleuropein aglycon counteracts AD-like pathology and cognitive impairments: an in vivo preclinical study
|
Casamenti, Fiorella
|
|
2014
|
35 |
S1 |
p. S5-
1 p.
|
artikel
|
| 77 |
Oral care and dementia
|
Müller, Frauke
|
|
2014
|
35 |
S1 |
p. S17-
1 p.
|
artikel
|
| 78 |
Parkinson's disease dementia: at the crossroads of α-synuclein, tau and amyloid-β
|
Irwin, David
|
|
2014
|
35 |
S1 |
p. S11-
1 p.
|
artikel
|
| 79 |
Preventive Drug trials for Alzheimer's disease.
|
Vellas, Bruno
|
|
2014
|
35 |
S1 |
p. S23-S24
2 p.
|
artikel
|
| 80 |
PrP — A piece of the puzzle, but where does it fit?
|
Klein, William L.
|
|
2014
|
35 |
S1 |
p. S12-
1 p.
|
artikel
|
| 81 |
Recent advances in tau imaging
|
Villemagne, Victor L.
|
|
2014
|
35 |
S1 |
p. S24-
1 p.
|
artikel
|
| 82 |
Recombinant human-derived monoclonal antibodies against A-beta aggregates for the treatment of Alzheimer's disease
|
Nitsch, Roger
|
|
2014
|
35 |
S1 |
p. S17-
1 p.
|
artikel
|
| 83 |
Repeated peripheral administration of adult mesenchymal stem cells has a positive impact on Abeta amyloid pathology in a transgenic mouse model of Alzheimer's disease
|
Bolmont, Tristan
|
|
2014
|
35 |
S1 |
p. S3-
1 p.
|
artikel
|
| 84 |
Shifted focus for target oriented basic research in Alzheimer disease
|
Winblad, Bengt
|
|
2014
|
35 |
S1 |
p. S25-
1 p.
|
artikel
|
| 85 |
Small molecules targeting the formation of neurotoxic oligomers for the treatment of AD/PD: a second look
|
Masliah, Eliezer
|
|
2014
|
35 |
S1 |
p. S15-
1 p.
|
artikel
|
| 86 |
Studying life-long vascular risk for late life dementia
|
Launer, Lenore J.
|
|
2014
|
35 |
S1 |
p. S13-S14
2 p.
|
artikel
|
| 87 |
Tau as a molecular biomarker in cerebrospinal fluid and plasma
|
Vanmechelen, Eugeen
|
|
2014
|
35 |
S1 |
p. S23-
1 p.
|
artikel
|
| 88 |
TauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX
|
Wischik, Claude M.
|
|
2014
|
35 |
S1 |
p. S26-
1 p.
|
artikel
|
| 89 |
The aging brain: beta-amyloid does not matter
|
Bouras, Constantin
|
|
2014
|
35 |
S1 |
p. S4-
1 p.
|
artikel
|
| 90 |
The Aging Brain - Does Amyloid Matter?
|
Sperling, Reisa
|
|
2014
|
35 |
S1 |
p. S21-
1 p.
|
artikel
|
| 91 |
The Merits of Activation of Protein Phosphatase-2A as a Therapeutic Approach to Alzheimer Disease and Related Tauopathies
|
Iqbal, Khalid
|
|
2014
|
35 |
S1 |
p. S11-
1 p.
|
artikel
|
| 92 |
The neglected targets in AD prevention and treatment
|
Korczyn, Amos D.
|
|
2014
|
35 |
S1 |
p. S13-
1 p.
|
artikel
|
| 93 |
The relevance of Quaternary structure to the functional effects of amyloid-β oligomers in the brain
|
Ashe, Karen
|
|
2014
|
35 |
S1 |
p. S2-
1 p.
|
artikel
|
| 94 |
The role of EEG in clinical trials on Alzheimer's disease
|
van Straaten, Ilse
|
|
2014
|
35 |
S1 |
p. S23-
1 p.
|
artikel
|
| 95 |
The spectrum of dementia with Lewy bodies (DLB)–prodromal to end-stage
|
McKeith, Ian G.
|
|
2014
|
35 |
S1 |
p. S15-
1 p.
|
artikel
|
| 96 |
The value of multi-PET tracers imaging for Alzheimer's disease therapy evolution
|
Nordberg, Agneta
|
|
2014
|
35 |
S1 |
p. S18-
1 p.
|
artikel
|
| 97 |
Toxicity of prions and prionoids: implications in neurodegenerative diseases
|
Aguzzi, Adriano
|
|
2014
|
35 |
S1 |
p. S1-
1 p.
|
artikel
|
| 98 |
Treatment of Psychosis in Parkinson's disease and Parkinson's disease dementia
|
Ballard, Clive
|
|
2014
|
35 |
S1 |
p. S2-
1 p.
|
artikel
|
| 99 |
Update on Tau imaging with F18-T807
|
Mintun, Mark
|
|
2014
|
35 |
S1 |
p. S16-
1 p.
|
artikel
|
| 100 |
Use it or lose it: environmental novelty, β2-adrenergic signaling, and the prevention of oAβ toxicity
|
Selkoe, Dennis
|
|
2014
|
35 |
S1 |
p. S20-
1 p.
|
artikel
|
| 101 |
Use of PET imaging to screen subjects for trials in prodromal and Mild Alzheimer's disease and the relationship between PET and CSF findings
|
Satlin, Andrew
|
|
2014
|
35 |
S1 |
p. S19-
1 p.
|
artikel
|
| 102 |
Vascular damage: a common target in most old age dementias
|
Gold, Gabriel
|
|
2014
|
35 |
S1 |
p. S9-
1 p.
|
artikel
|
| 103 |
Vascular risk factors, professional activity, life expectancy and memory complaints of CERN's retirees
|
Herrmann, François
|
|
2014
|
35 |
S1 |
p. S10-
1 p.
|
artikel
|
| 104 |
Visual symptoms and their management in dementia
|
Mosimann, Urs Peter
|
|
2014
|
35 |
S1 |
p. S16-S17
2 p.
|
artikel
|
| 105 |
What we expect from future trials
|
Schneider, Lon S.
|
|
2014
|
35 |
S1 |
p. S19-S20
2 p.
|
artikel
|
| 106 |
Which Tau species are toxic? Consequences for therapeutic approaches
|
Dujardin, S.
|
|
2014
|
35 |
S1 |
p. S4-
1 p.
|
artikel
|
| 107 |
Why did animal models fail to show the right way to Alzheimer Therapy?
|
Windisch, Manfred
|
|
2014
|
35 |
S1 |
p. S25-S26
2 p.
|
artikel
|
Tijdschrift beschrijving